Hypermethylated Genes of MicroRNA in Ovarian Carcinoma: Metastasis Prediction Marker Systems


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅存取

详细

We identified a group of miRNA genes whose methylation is associated with ovarian cancer metastasis. Based on these data, new markers and the systems of markers predicting tumor dissemination were selected. Using methylation-specific PCR and a representative set of 54 ovarian cancer samples, we identified 10 microRNA genes (MIR-124a-2, MIR-127, MIR-125b-1, MIR-129-2, MIR-137, MIR-193a, MIR-203a, MIR-34b/c, MIR-130b, and MIR-1258) whose methylation is associated with tumor metastasis. The greatest association was established for 4 genes: MIR-137, MIR-193a, MIR-34b/c, and MIR-130b (p<0.01). ROC analysis revealed 3 most optimal marker systems including 4-5 miRNA genes and characterized by high sensitivity (82-94%) and specificity (76-86%) at AUC=0.89-0.92. Methylation of any three genes from these systems is sufficient to predict metastasis with the specified accuracy. Detection of the group of hypermethylated miRNA genes with predictive value for ovarian cancer metastasis is of great importance for personalized treatment of the patients.

作者简介

E. Filippova

Research Institute of General Pathology and Pathophysiology

Email: eleonora10_45@mail.ru
俄罗斯联邦, Moscow

V. Loginov

Research Institute of General Pathology and Pathophysiology; Research Center for Medical Genetics

Email: eleonora10_45@mail.ru
俄罗斯联邦, Moscow; Moscow

A. Burdennyi

Research Institute of General Pathology and Pathophysiology

Email: eleonora10_45@mail.ru
俄罗斯联邦, Moscow

E. Braga

Research Institute of General Pathology and Pathophysiology; Research Center for Medical Genetics

编辑信件的主要联系方式.
Email: eleonora10_45@mail.ru
俄罗斯联邦, Moscow; Moscow

I. Pronina

Research Institute of General Pathology and Pathophysiology

Email: eleonora10_45@mail.ru
俄罗斯联邦, Moscow

T. Kazubskaya

N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation

Email: eleonora10_45@mail.ru
俄罗斯联邦, Moscow

D. Kushlinskii

N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation

Email: eleonora10_45@mail.ru
俄罗斯联邦, Moscow

D. Utkin

N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation

Email: eleonora10_45@mail.ru
俄罗斯联邦, Moscow

M. Fridman

N. I. Vavilov Institute of General Genetics, Russian Academy of Sciences

Email: eleonora10_45@mail.ru
俄罗斯联邦, Moscow

D. Khodyrev

Federal Scientific and Clinical Center of Specialized Medical Care and Medical Technologies, Federal Medical-Biological Agency of the Russia

Email: eleonora10_45@mail.ru
俄罗斯联邦, Moscow

N. Kushlinskii

N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation

Email: eleonora10_45@mail.ru
俄罗斯联邦, Moscow


版权所有 © Springer Science+Business Media, LLC, part of Springer Nature, 2019
##common.cookie##